An overseas brand that sells at home may never have filed a cosmetic before, because some markets place the burden on the importer or ask little at launch. China works differently: a product usually needs a filing or registration on record before it is placed on sale, & the step sits between the formula & the shelf. The brand that learns this after the goods are made is the one that misses a season.
This article sets out who usually holds the filing for an overseas brand, which documents travel with a first submission, & what a factory can realistically support without becoming the responsible party. It is written for the brand owner or the market-entry lead who has to plan the timeline, not for the local representative who will lodge the papers.
Why overseas brands face a filing step before sale in China
The Chinese system regards the right to place a cosmetic on the market as something that has to be recorded with the authority first, rather than something assumed once the product exists. The depth of the step depends on the product type, with some categories needing a fuller review than others, but the step itself applies broadly to products sold to local consumers through any channel.
For an overseas brand the practical effect is that the product cannot simply be shipped & listed. A dossier has to be prepared, a responsible entity has to be in place locally, & the supporting test reports have to back the formula & the claims. The work is front-loaded, which is why it belongs in the launch plan rather than in a rush after production.
The cost of missing this is a held shipment or a blocked listing, & the cost lands at the worst moment because the goods are already made. A brand that regards the filing as a paperwork afterthought usually discovers the afterthought takes longer than the manufacturing did, & the calendar does not wait.
Who holds the filing: the domestic responsible entity
The filing is held by a domestic responsible entity, which is the party the authority can reach inside the market. An overseas brand without a local presence normally works through a local representative, agent or subsidiary that takes on that role, & the choice of entity decides who answers questions during the life of the product.
The factory, even one based in the same country, is generally not the holder for an overseas brand's own product, because the responsibility sits with the party placing the product on the local market. A maker can prepare the technical files & the samples, but the filing itself is usually lodged by the responsible entity, not by the contract manufacturer.
The lesson for the brief is to name the responsible entity early & to confirm it can hold the duties the role carries. A brand that reaches launch without a settled entity has a product it cannot lawfully place on sale, & no amount of manufacturing readiness fixes a missing local responsible party.
Which documents travel with a first filing
A first filing usually travels with a set of documents that describe the product & support its safety. The set typically includes the formula with quantities, the manufacturing information, the safety assessment, the labelling copy & the test reports that back the dossier. The exact list depends on the product type & should be confirmed against the current official text.
The formula is the centrepiece. It has to name the ingredients & their levels in a form the authority recognises, & it has to match the product that is actually made, because a formula that drifts from the submitted version is a problem the brand has to answer later. The factory's batch record & the submitted formula should be the same story.
The labelling copy is the second piece that surprises brands. The claims, the warnings & the presentation have to sit within the boundaries the rules allow, & copy written for another market may not transfer. A brand that submits artwork built for home & expects it to pass unchanged often rewrites it, which is a delay & a cost that a brief-stage review would have caught.
The formula & the supporting test reports
The formula drives most of the test burden. Some ingredients require specific reports, some product types require a broader set, & the responsible entity usually decides the exact categories once the formula is final. A brand that changes the formula after testing has started may reopen the reports, which is why the formula should be locked before the samples go to the lab.
The test reports are the evidence behind the dossier, & they have to be issued by an accepted route for the market. A report from a lab that is not recognised for the purpose is a document the brand cannot use, & discovering that after the work is done is a full redo. The route should be confirmed before the samples are sent, not after the results return.
The factory's role here is to supply the formula, the manufacturing detail & the samples in a state the lab can work with, & to confirm the batch made for sale matches the batch tested. A mismatch between the tested sample & the sold product is the kind of gap a review will find, & it is cheaper to prevent than to explain.
Labelling & claim boundaries under the filing
The claims a brand can make are bounded by what the dossier supports, & the boundaries differ from those in other markets. Copy that is acceptable at home may sit outside what the local rules permit, so the label & the listing copy should be reviewed against the local position before they are printed. The factory does not set these boundaries; the responsible entity & an adviser do.
The practical risk is a claim that cannot be substantiated in the local frame, which can block the filing or force a rewrite. A brand should regard the claim list as part of the dossier, not as a marketing add-on, & should agree the permitted wording with the responsible entity before the artwork is locked. The cost of a late claim change is a reprint & a slipped date.
The ingredient labelling also follows local format expectations, & the INCI or equivalent listing has to be presented in the recognised way. A reader of INCI names & global ingredient safety rules will see how ingredient presentation varies by market, which is the kind of detail that should be checked rather than assumed when the label is built.
The timeline reality: what a first filing usually meets
The timeline is the part brands underestimate, because it runs in parallel with manufacturing rather than after it. The formula has to be final before testing, the tests have to finish before the dossier is complete, & the dossier has to be lodged by the responsible entity before sale. Each stage has its own lead time, & they do not compress by wishing.
| Stage | What it needs from the brand | What the factory supplies | Slip risk if handled late |
|---|---|---|---|
| Formula finalisation | Locked ingredient list & levels | Base formula & manufacturing detail | Retesting if the formula moves |
| Sample preparation | Agreed batch for the lab | Representative production sample | A sample that does not match sale stock |
| Testing | Accepted lab route chosen | Formula & spec to the lab | A report the authority will not accept |
| Dossier build | Labelling & claim review | Manufacturing & safety inputs | Artwork rewrite under time pressure |
| Responsible entity | Local party appointed | Technical file handover | No lawful holder for the filing |
| Submission | Entity lodges the dossier | Confirmed batch consistency | A launch blocked at the border |
| Post-approval | Change control agreed | Updated records on change | A live product out of file |
The rows describe a typical sequence, not a fixed schedule, because the actual duration depends on the product type, the test categories & the readiness of the documents. A qualified regulatory adviser & the responsible entity should set the realistic timeline for the specific product before a launch date is promised to a retailer.
Testing categories a brand should expect
The tests a product meets depend on its type & its claims, & the responsible entity usually maps the exact categories once the formula is known. A brand should expect the set to cover the basics for a cosmetic & to widen where the product or the claim invites closer review. The point is to plan for the wider set rather than hope for the narrow one.
The factory cannot decide the categories, but it can shorten the loop by supplying a clean formula, a consistent sample & the manufacturing detail the lab needs. A brand that receives a vague formula from the maker spends the first weeks of the timeline just making the document usable, which is time taken from the clock that does not stop.
The budget line matters. Testing is a real cost that recurs if the formula changes, so a brand should regard formula stability as a money decision as much as a science one. A formula locked once, tested once & filed once is cheaper than a formula that moves twice & tests twice before the product ever sells.
Renewal, change & the living file
A filing is not a one-time event for the life of the product; it is a file that has to stay consistent with what is sold. A change to the formula, the pack, the claims or the responsible entity can trigger an update, & the brand that regards the approved dossier as fixed will eventually fall out of step with the product on the shelf.
The discipline is change control. When a material is substituted or a claim is trimmed, the brand should ask whether the file still matches, & should route the change through the responsible entity rather than shipping the new version & hoping no one notices. A silent change is the most common way a live product drifts from its record.
The factory supports this by keeping the batch record, the specification & the retention sample so that any question about what was actually made can be answered from evidence. A reader of the documents private label brands usually need will see how the same records feed both the factory audit & the market file.
Common mistakes overseas brands make
The first mistake is assuming home-market approval travels. A product cleared elsewhere is not cleared locally, & the dossier has to be built for the market even when the formula is unchanged. A brand that ships on the strength of a foreign approval learns the gap at the border or the listing gate.
The second is leaving the responsible entity until after manufacturing. The entity is needed to lodge the dossier, & without it the product cannot be placed on sale no matter how ready the factory is. The appointment should sit in the brief alongside the formula, not in a note added during the first delay.
The third is changing the formula after testing starts. Each move can reopen reports & reset part of the timeline, & the brand that regards the formula as flexible during this window pays for that flexibility in weeks. Locking the formula before the lab is the cheapest schedule defence a brand has.
How a factory supports the filing without holding it
A contract manufacturer supports the filing by supplying the technical backbone: the formula, the manufacturing method, the specification, the batch record & the samples. It does not usually hold the filing for an overseas brand's own product, because the responsible entity is the local party, & the two roles should not be confused in the brief.
The value a good factory adds is consistency. When the batch made for sale matches the batch tested & the submitted formula, the dossier stays defensible, & a question from the authority can be answered from the factory's own records. Inconsistency is what turns a routine query into a crisis, & consistency is built at the bench, not patched later.
The brand should ask the factory for a document package it can hand to the responsible entity without rebuilding it, & should confirm the package covers the formula, the manufacturing detail & the sample identity. A buyer can also read our notes on how Chinese manufacturers approach export compliance to see how a factory frames the technical file for multiple markets at once.
What to put in the brief
An overseas-brand brief for the Chinese market has to name the responsible entity & the product type up front, because those two decide the depth of the dossier & the timeline the brand must plan. Set them before the formula is finalised, so the testing & the submission run in parallel with manufacturing rather than after it.
- The responsible local entity that will hold the filing, & the duties it accepts.
- The product type & the claims intended, because they set the test categories.
- The final formula & levels, locked before samples go to the lab.
- The labelling copy reviewed against local boundaries before artwork is printed.
- The accepted test route, confirmed so the reports will be usable.
- The factory document package: formula, method, spec, batch record, sample.
- The change-control rule, so a later tweak updates the file.
- The review trigger that sends the dossier back to an adviser when a rule moves.
Then hand the factory package to the responsible entity as a clean set, & keep the sold product matching the filed one. The brief is what keeps the dossier & the shelf in step, & the step is easier when it is planned than when it is discovered.
Where our capability fits
We prepare the technical backbone a filing needs: the formula, the manufacturing method, the specification, the batch record & the representative samples, & we keep the sold batch consistent with the tested one so the dossier stays defensible. We do not hold the filing for an overseas brand's own product; that sits with the responsible local entity, & we hand the package to them rather than standing in their place.
We work with brands on private label (your brand on a proven base), OEM/ODM contract manufacturing & full custom formula development, & the document depth is set at the brief stage so the package is ready when the responsible entity needs it. Our lines include an amino acid facial cleanser, a firming face cream & custom softgel facial serum capsules, all produced with the same formula & retention discipline a market file depends on.
Tell us the markets you sell into & the responsible entity you will use, & we will come back with the document package, the sample plan & the consistency checks needed before submission. Start at our inquiry page, email capsulebiotech@163.com, or message the right team on WhatsApp: Capsule Series (capsules only) +86 158-7655-5319, Cosmetics Series (serum, hair care, body care, fragrance) +86 158-7655-5319.
General manufacturing information, not regulatory or legal advice. Filing duties, document categories & notification requirements vary by product & by market & change over time; the official text & a qualified regulatory adviser govern, & this article should be confirmed against the current rules for each destination before a product is placed on sale.